Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy
- PMID: 17326614
- DOI: 10.1021/jm061062o
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy
Abstract
A series of 2,4-dinitrobenzamide mustards were prepared from 5-chloro-2,4-dinitrobenzoic acid or the corresponding 5-dimesylate mustard as potential prodrugs for gene-directed enzyme prodrug therapy (GDEPT) with the E. coli nfsB nitroreductase (NTR). The compounds, including 32 new examples, were evaluated in four pairs of NTR+ve/-ve cell lines for selective cytotoxicity (IC50 and IC50 ratios), in multicellular layer (MCL) cultures for bystander effects, and for in vivo activity against tumors grown from stably NTR transfected EMT6 and WiDr cells in nude mice. Multivariate regression analysis of the IC50 results was undertaken using a partial least-squares projection to latent structures model. In NTR-ve lines, cytotoxicity correlated positively with logP, negatively with hydrogen bond acceptors (HA) and donors (HD) in the amide side chain, and positively with the reactivity of the less-reactive leaving group of the mustard function, likely reflecting toxicity due to DNA monoadducts. Potency and selectivity for NTR+ve lines was increased by logP and HD, decreased by HA, and was positively correlated with the leaving group efficiency of the more-reactive group, likely reflecting DNA crosslinking. NTR selectivity was greatest for asymmetric chloro/mesylate and bromo/mesylate mustards. Bystander effects in the MCL assay also correlated positively with logP and negatively with leaving group reactivity, presumably reflecting the transcellular diffusion/reaction properties of the activated metabolites. A total of 18 of 22 mustards showed equal or greater bystander efficiencies in MCLs than the aziridinylbenzamide CB 1954, which is currently in clinical trial for NTR-GDEPT. The dibromo and bromomesylate mustards were surprisingly well tolerated in mice. High MTD/IC50 (NTR+ve) ratios translated into curative activity of several compounds against NTR+ve tumors. A bromomesylate mustard showed superior activity against WiDr tumors grown from 1:9 mixtures of NTR+ve and NTR-ve cells, indicating a strong bystander effect in vivo.
Similar articles
-
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.J Med Chem. 2003 Dec 4;46(25):5533-45. doi: 10.1021/jm030308b. J Med Chem. 2003. PMID: 14640560
-
Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.J Med Chem. 2003 Jun 5;46(12):2456-66. doi: 10.1021/jm0205191. J Med Chem. 2003. PMID: 12773049
-
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.J Med Chem. 2004 Jun 3;47(12):3295-307. doi: 10.1021/jm0498699. J Med Chem. 2004. PMID: 15163209
-
Nitroreductase-based GDEPT.Curr Pharm Des. 2002;8(15):1349-61. doi: 10.2174/1381612023394584. Curr Pharm Des. 2002. PMID: 12052212 Review.
-
Virus-directed enzyme prodrug therapy using CB1954.Anticancer Drug Des. 1999 Dec;14(6):461-72. Anticancer Drug Des. 1999. PMID: 10834268 Review.
Cited by
-
Asymmetric and Reduced Xanthene Fluorophores: Synthesis, Photochemical Properties, and Application to Activatable Fluorescent Probes for Detection of Nitroreductase.Molecules. 2019 Sep 3;24(17):3206. doi: 10.3390/molecules24173206. Molecules. 2019. PMID: 31484448 Free PMC article.
-
Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.Pharmaceuticals (Basel). 2022 Feb 1;15(2):185. doi: 10.3390/ph15020185. Pharmaceuticals (Basel). 2022. PMID: 35215297 Free PMC article.
-
Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.Front Pharmacol. 2018 Sep 18;9:1013. doi: 10.3389/fphar.2018.01013. eCollection 2018. Front Pharmacol. 2018. PMID: 30279659 Free PMC article.
-
Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit.Cancer Gene Ther. 2022 Jul;29(7):1021-1032. doi: 10.1038/s41417-021-00409-2. Epub 2021 Nov 26. Cancer Gene Ther. 2022. PMID: 34837065
-
E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.Br J Cancer. 2009 Jun 16;100(12):1903-11. doi: 10.1038/sj.bjc.6605094. Epub 2009 May 19. Br J Cancer. 2009. PMID: 19455141 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources